Cancer Family
Skin Neoplasm
CI-CAN-00000051Explore in graph →
Non-malignant346 active trials14 approved drugs74 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000051Explore in graph →
Clinical trials
1,424 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04101331 | Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides(REDIRECT) | completed | Phase 2 | 108 | Affimed GmbHINDUSTRY | 10 | Nov 5, 2024 | clinicaltrials |
| NCT03493451 | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms | completed | Phase 2 | 77 | BeiGeneINDUSTRY | 5 | Oct 26, 2024 | clinicaltrials |
| NCT03714828 | Study of TVEC in Patients With Cutaneous Squamous Cell Cancer | completed | Phase 2 | 11 | University of ArizonaOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT01740557 | Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stage III or Metastatic Melanoma | completed | Phase 1 / Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT05896215 | OM202JP Clinical Study of KNP2002 | completed | Phase 2 | 159 | KinoPharma Inc.INDUSTRY | 1 | Sep 27, 2024 | clinicaltrials |
| NCT02953301 | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)(RESMAIN) | completed | Phase 2 | 201 | 4SC AGINDUSTRY | 12 | Aug 30, 2024 | clinicaltrials |
| NCT02431676 | Survivorship Promotion In Reducing IGF-1 Trial(SPIRIT) | completed | Phase 2 | 121 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2024 | clinicaltrials |
| NCT05713760 | Proof of Concept Study to Access Superficial Basal Cell Carcinoma in Adults | completed | Phase 2 | 5 | Austin Institute for Clinical ResearchNETWORK | 1 | Jul 19, 2024 | clinicaltrials |
| NCT02964559 | Pembrolizumab in Patients With Locally Advanced or Metastatic Skin Cancer | completed | Phase 2 | 11 | Emory UniversityOTHER | 1 | Jun 26, 2024 | clinicaltrials |
| NCT01226472 | Extension Study in Subjects Who Relapsed After Complete Response on Study KW-0761-001 | completed | Phase 2 | 1 | Kyowa Kirin Co., Ltd.INDUSTRY | 1 | Apr 25, 2024 | clinicaltrials |
| NCT05877313 | Nitric Oxide Releasing Solution (NORS) For The Treatment Of Human Papillomavirus(HPV) Verrucae Plantaris (Plantar Warts) | completed | Phase 2 | 20 | Sanotize Research and Development corp.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT02519322 | Neoadjuvant and Adjuvant Checkpoint Blockade | completed | Phase 2 | 53 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT03110159 | DUSA: Cyclic PDT for the Prevention of AK & NMSC in Solid Organ Transplant Recipients | completed | Phase 1 / Phase 2 | 8 | Medical Dermatology SpecialistsOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT03012581 | Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types(AcSé) | completed | Phase 2 | 269 | UNICANCEROTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT02839720 | Selumetinib in Treating Patients With Neurofibromatosis Type 1 and Cutaneous Neurofibroma | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06152367 | Immunization With Autologous Dendritic Cells and Tumor Lysates in Melanoma Patients | completed | Phase 1 / Phase 2 | 90 | University of ChileOTHER | 1 | Nov 30, 2023 | clinicaltrials |
| NCT00047060 | Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome | completed | Phase 1 / Phase 2 | 5 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Nov 14, 2023 | clinicaltrials |
| NCT03701295 | Pinometostat and Azacitidine in Treating Patients With Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia With 11q23 Rearrangement | completed | Phase 1 / Phase 2 | 1 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2023 | clinicaltrials |
| NCT02304458 | Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas | completed | Phase 1 / Phase 2 | 140 | National Cancer Institute (NCI)NIH | 2 | Oct 17, 2023 | clinicaltrials |
| NCT03602079 | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene | completed | Phase 1 / Phase 2 | 49 | Klus Pharma Inc.INDUSTRY | 1 | Aug 3, 2023 | clinicaltrials |
| NCT05380635 | PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma | completed | Phase 2 | 9 | SoligenixINDUSTRY | 1 | Jun 7, 2023 | clinicaltrials |
| NCT00071071 | Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in the Skin. | completed | Phase 2 | 25 | GenmabINDUSTRY | 1 | May 18, 2023 | clinicaltrials |
| NCT00896493 | Ph II of Non-myeloablative Allogeneic Transplantation Using TLI & ATG In Patients w/ Cutaneous T Cell Lymphoma | completed | Phase 2 | 38 | Stanford UniversityOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT00071084 | Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma in the Skin. | completed | Phase 2 | 22 | GenmabINDUSTRY | 4 | Apr 28, 2023 | clinicaltrials |
| NCT02546440 | Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)(DMF-CTCL) | completed | Phase 2 | 25 | Universitätsmedizin MannheimOTHER | 1 | Mar 31, 2023 | clinicaltrials |
| NCT03109353 | Modification of Extracorporeal Photopheresis in Cutaneous T-cell Lymphoma or Chronic Graft-versus-host Disease | completed | Phase 1 / Phase 2 | 7 | St. Olavs HospitalOTHER | 1 | Jan 13, 2023 | clinicaltrials |
| NCT02643303 | A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers | completed | Phase 1 / Phase 2 | 58 | Ludwig Institute for Cancer ResearchOTHER | 1 | Dec 2, 2022 | clinicaltrials |
| NCT01807182 | Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 11 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 10, 2022 | clinicaltrials |
| NCT00520299 | Study of ADI-PEG 20 in Patients With Advanced Melanoma | completed | Phase 1 / Phase 2 | 31 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 25, 2022 | clinicaltrials |
| NCT03396952 | Prostaglandin Inhibition and Immune Checkpoint Blockade in Melanoma | completed | Phase 2 | 27 | University of California, San FranciscoOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT00679289 | Phase II Study of KW2871 Combined With High Dose Interferon-α2b in Patients With Metastatic Melanoma | completed | Phase 2 | 36 | Ludwig Institute for Cancer ResearchOTHER | 1 | Oct 12, 2022 | clinicaltrials |
| NCT02218164 | Capecitabine or 5-FU With Pegylated Interferon Alpha-2b in Unresectable/Metastatic Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 8 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Oct 7, 2022 | clinicaltrials |
| NCT04435665 | NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 48 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Aug 9, 2022 | clinicaltrials |
| NCT03633110 | Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine | completed | Phase 1 / Phase 2 | 24 | Genocea Biosciences, Inc.INDUSTRY | 1 | Apr 19, 2022 | clinicaltrials |
| NCT05315128 | Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers | completed | Phase 2 | 60 | Zagazig UniversityOTHER_GOV | 1 | Apr 7, 2022 | clinicaltrials |
| NCT02129075 | A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 16, 2021 | clinicaltrials |
| NCT00425555 | Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma | completed | Phase 2 | 139 | Novartis PharmaceuticalsINDUSTRY | 12 | Aug 20, 2021 | clinicaltrials |
| NCT02676778 | Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma | completed | Phase 2 | 45 | Eisai Co., Ltd.INDUSTRY | 1 | Jul 15, 2021 | clinicaltrials |
| NCT03180528 | Topical Remetinostat in Treating Patient With Cutaneous Basal Cell Cancer | completed | Phase 2 | 30 | Kavita SarinOTHER | 1 | Jun 8, 2021 | clinicaltrials |
| NCT03239392 | A Dose-Ranging Study of IV BNZ-1 in LGL Leukemia or Refractory CTCL | completed | Phase 1 / Phase 2 | 50 | Bioniz TherapeuticsINDUSTRY | 1 | May 25, 2021 | clinicaltrials |
| NCT01835626 | Phase II Study of Radiation Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma | completed | Phase 2 | 24 | Sue YomOTHER | 1 | May 3, 2021 | clinicaltrials |
| NCT03292406 | A Safety, Efficacy and Pharmacokinetics Study of CD11301 for the Treatment of Cutaneous T-Cell Lymphoma (CTCL)(CTCL) | completed | Phase 2 | 86 | Galderma R&DINDUSTRY | 3 | Apr 8, 2021 | clinicaltrials |
| NCT00489203 | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 140 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 3, 2021 | clinicaltrials |
| NCT02423863 | In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol®(Poly-ICLC) | completed | Phase 2 | 26 | Oncovir, Inc.INDUSTRY | 1 | Dec 17, 2020 | clinicaltrials |
| NCT01258998 | Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Nov 4, 2020 | clinicaltrials |
| NCT00744991 | A Study for Participants With Relapsed Cutaneous T-Cell Lymphoma | completed | Phase 2 | 25 | Eli Lilly and CompanyINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT02347813 | Preventing Squamous Cell Skin Cancer | completed | Phase 2 | 12 | University of RochesterOTHER | 0 | Jun 23, 2020 | clinicaltrials |
| NCT01198028 | Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma | completed | Phase 2 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2020 | clinicaltrials |
| NCT00918333 | Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 124 | Mayo ClinicOTHER | 1 | Mar 10, 2020 | clinicaltrials |
| NCT02705352 | 5-fluorouracil Versus Placebo in Periocular Full Thickness Skin Grafts | completed | Phase 2 | 1 | Massachusetts Eye and Ear InfirmaryOTHER | 1 | Mar 9, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Nov 5, 2024source: clinicaltrials